Ngakan Putu Parsama Putra
Universitas Brawijaya

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

Analysis of Comorbidity and Its Association with Disease Severity and Mortality Rate in Hospitalized COVID-19 Patients Anthony Christanto; Aditya Sri Listyoko; Ngakan Putu Parsama Putra
Jurnal Respirologi Indonesia Vol 42, No 1 (2022)
Publisher : Perhimpunan Dokter Paru Indonesia (PDPI)/The Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/jri.v42i1.278

Abstract

Background: Comorbidity is a major factor in determining the outcome of COVID-19. However, existing studies regarding comorbidities and the disease severity and mortality of COVID-19 are mostly based on studies in the whole community, and not on those admitted to hospitals. This study aims to determine the demographic profile of comorbidities among COVID-19 patients hospitalized in tertiary care referral hospitals and its association with disease severity and mortality. Methods: We analyzed the data from 60 laboratory-confirmed patients in our hospital in Malang City, East Java, Indonesia from March 12th, 2020 to June 5th, 2020. We describe the demographic profile of the patients and perform statistical analysis to determine its relationship to disease severity and mortality. Results: The majority of the study samples (66.7%) were categorized as having a severe disease. Thirty-seven samples (61.7%) had at least one comorbidity. The mortality rate among the study population is 30.0%, and 37.8% among those with comorbidities. The most prevalent comorbidity was hypertension (40.0%), followed by heart failure (35.0%) and diabetes (25.0%). There is a statistically significant relationship between the presence of comorbidities and disease severity and between disease severity and mortality (p<0.05). Diabetes was the only comorbidity with a significant relationship towards mortality in our study (p<0.05, OR 4.0 95% CI 1.16-13.74). Conclusion: Comorbidities are associated with worse disease severity and death in hospitalized COVID-19 patients. 
Differences in Levels of Human 1,3β-D-Glucan from Bronchoalveolar Lavage (BAL) Fluid in The Immunocompromised and Immunocompetent Groups Patients with Suspected Lung Cancer Asih Trimurtini; Ngakan Putu Parsama Putra; Teguh Rahayu Sartono; Harun Al Rasyid
Jurnal Respirologi Indonesia Vol 42, No 2 (2022)
Publisher : Perhimpunan Dokter Paru Indonesia (PDPI)/The Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/jri.v42i2.298

Abstract

Background: Invasive candidiasis occurs in immunocompromised individuals as an opportunistic infection in patients with lung cancer. Although culture and histopathology remain the standard diagnosis of fungal infections, other tests are still needed to provide faster results. Human 1,3-β-D-Glucan (BDG) uses ELISA to detect candidiasis. β D-Glucan level from BAL fluid is positive when the cut-off is p 130 pg / mL. This study aims to determine differences in the levels of Human 1,3β-D-Glucan from Bronchoalveolar Lavage (BAL) fluid between the immunocompromised and immunocompetent groups in patients with suspected lung cancer at RSU Dr. Saiful Anwar Malang.Method: A cross-sectional study was conducted on 33 lung cancer patients who had risk factors for invasive candidiasis in Dr. Saiful Anwar Hospital Malang.Result: 33 study patients had significant differences in BAL levels of Human 1,3β-D-Glucan in the immunocompromised and immunocompetent groups (p = 0.009). In the different tests, there was a slight difference in the levels of BAL Human 1,3β-D-Glucan but it was not statistically significant based on age and sex in the immunocompromised and immunocompetent groups (p = 0.632, p = 0.338, p = 0.472, p = 0.667).Conclusion: Patients suspected of lung cancer have risk factors for invasive candidiasis with higher BDG levels due to immunoparalysis. There were significant differences in the BAL Human levels of 1,3β-D-Glucan in the immunocompromised and immunocompetent groups.